Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 53 people in total — 27 in one group who used a mometasone furoate nasal irrigation (a steroid medication delivered as a rinse through the nose) and 26 in a second group who used a mometasone nasal spray (the same type of steroid delivered as a spray). Of those, 22 and 21 people respectively completed the trial. The trial was measuring changes in sinus and nasal symptoms, participants' own sense of how they responded to treatment, and physical findings seen during a camera examination of the nose. The reported data shows that for the main outcome — a symptom questionnaire called the SNOT-22, which runs from 0 (no problems) to 110 (worst possible) — the average change in score was reported as 23.18 points for the nasal irrigation group and 17.7 points for the nasal spray group. The data does not specify whether these figures represent the final score or the amount of change from the start, so the exact meaning of these numbers cannot be confirmed from what was submitted. For one of the secondary outcomes, participants were asked to rate their overall response to treatment on a 7-point scale; a score below 3 indicated at least "much improved." The reported data shows that 22 out of 22 completers in the nasal irrigation group and 20 out of 21 completers in the nasal spray group scored below 3 on that scale. For the nasal camera examination, which scores inflammation in the nose from 0 to 12, the reported average scores were 2.2 for the nasal irrigation group and 2.1 for the nasal spray group; it was not reported whether these were final scores or changes from the starting point. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 15577816) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 4 Chronic Rhinosinusitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have had two or more of the following symptoms for 12 weeks or longer: thick or discolored nasal discharge (from the front or back of the nose), a blocked or stuffy nose, pain or pressure or a feeling of fullness in your face, or a reduced sense of smell
- A doctor has confirmed signs of inflammation in your sinuses, either by looking inside your nose and finding mucus or swelling in certain areas, or through an imaging scan (like a CT scan) showing inflammation in your sinuses
Who may not be able to join:
- You are not able to speak or understand English
- You have nasal polyps (small, soft growths inside the nose)
- You have had surgery on your nose or sinuses in the past
- You have a condition that affects how your nose and airways clear mucus (confirm with trial site)
- You rely on long-term steroid medications for another condition, such as asthma or chronic obstructive pulmonary disease (a lung condition)
- You have taken antibiotic tablets or capsules in the past 2 weeks
- You have a known allergy to mometasone furoate (a type of nasal steroid spray) or other similar steroid products
- You are currently pregnant or breastfeeding
- Your symptom score on a specific sinus questionnaire (called the SNOT-22) is 9 or below, as this would make it difficult to measure meaningful improvement during the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Sino-Nasal Outcome Test Scores (SNOT-22)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.